Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal

Authors

  • Tuhina Neogi,

    1. Boston University School of Medicine, Boston, Massachusetts
    Search for more papers by this author
    • Drs. Neogi and George contributed equally to this work.

  • Jacob George,

    1. University of Dundee Medical School, Dundee, UK
    Search for more papers by this author
    • Drs. Neogi and George contributed equally to this work.

  • Sushma Rekhraj,

    1. University of Dundee Medical School, Dundee, UK
    Search for more papers by this author
  • Allan D. Struthers,

    1. University of Dundee Medical School, Dundee, UK
    Search for more papers by this author
    • Dr. Struthers holds a patent for the use of xanthine oxidase inhibitors in angina treatment.

  • Hyon Choi,

    1. Boston University School of Medicine, Boston, Massachusetts
    Search for more papers by this author
    • Dr. Choi has received honoraria for service on advisory boards for Takeda, URL Pharma, and Savient (less than $10,000 each).

  • Robert A. Terkeltaub

    Corresponding author
    1. VA San Diego Medical Center and University of California, San Diego
    • VA San Diego Medical Center, Rheumatology 111K, 3350 La Jolla Village Drive, San Diego, CA 92161
    Search for more papers by this author
    • Dr. Terkeltaub has received consulting fees, speaking fees, and/or honoraria from URL Pharma, Takeda, Savient, Novartis, Pfizer, Regeneron, Ardea Biosciences, and BioCryst (less than $10,000 each) and has provided paid consultation to Leerink Swann on the topic of gout.


Ancillary